On Monday, TD (TSX:TD) Cowen adjusted its stance on agilon health Inc (NYSE:AGL), downgrading the company's stock from Outperform to Market Perform and significantly reducing the price target to $6.50 from the previous $12.00. The revision follows a challenging period for the healthcare company, which recently reported a significant shortfall in its earnings guidance.
The firm's decision to downgrade was influenced by agilon health's January announcement, where it revealed that its EBITDA projections for 2024 would be 50% lower than expected. Additionally, the company withdrew its 2026 outlook and disclosed the retirement of its CFO. Despite these setbacks and the subsequent drop in the stock's value to below 0.4x its 2025 EV/Sales, TD Cowen had initially maintained its Outperform rating, attributing some strategic value to the company even with the lowest estimates on the Street.
The recent revelation that agilon health's largest payor partners had not adequately underwritten the 2024 Medicare Advantage risk was a key factor in the analyst's reassessment. This underwriting shortfall is anticipated to introduce additional margin risk that will likely impact agilon health's financial performance, prompting the firm to revise its rating and price target for the healthcare provider's shares.
The price target adjustment to $6.50 reflects a significant decrease from the previous target of $12.00, indicating a more conservative outlook on the company's future share value. This change in target is a direct result of the newly identified risks and the company's updated financial guidance.
Agilon health's stock performance and future prospects are now being viewed with greater caution by TD Cowen, as indicated by the shift to a Market Perform rating. This suggests a neutral expectation of the stock's performance relative to the broader market going forward.
InvestingPro Insights
In light of TD Cowen's recent downgrade of agilon health Inc (NYSE:AGL), it's worth considering additional insights provided by InvestingPro. Notably, management's aggressive share buyback activity signals a conviction in the company's intrinsic value, which may offer some reassurance to investors after the recent earnings guidance shortfall. This is complemented by the fact that agilon health holds more cash than debt on its balance sheet, providing a level of financial stability amidst the current uncertainties.
From a valuation perspective, agilon health's stock has been trading at a low revenue valuation multiple, which could indicate a potential investment opportunity for those who believe in the company's long-term strategy and market position. However, it is important to note that analysts are not expecting the company to be profitable this year, and it has not been profitable over the last twelve months, which could be a cause for concern.
InvestingPro Data further shows a significant revenue growth of 68.89% over the last twelve months as of Q3 2023, which may reflect the company's ability to increase sales despite the challenges it faces. Nevertheless, with a negative P/E Ratio (Adjusted) of -28.61 and a Gross Profit Margin of just 4.17%, the company's profitability is under pressure.
For those interested in further analysis and tips, there are additional InvestingPro Tips available that could provide deeper insights into agilon health's financial health and market performance. For a more comprehensive understanding, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes access to these valuable tips.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.